Additional antihypertensive effect of magnesium supplementation with an angiotensin II receptor blocker in hypomagnesemic rats

Korean Journal of Internal Medicine

Volumn 28, Issue 2, 2013, Pages 197-205

  Jin, Kyubok ^a   Kim, Tae Hee ^a   Kim, Yeong Hoon ^a   Kim, Yang Wook ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

Angiotensin receptor antagonists; Hypertension; Magnesium

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM; LOSARTAN; MAGNESIUM; POTASSIUM; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER;

ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DIET SUPPLEMENTATION; HYPERTENSION; HYPOMAGNESEMIA; INFLAMMATION; KIDNEY PARENCHYMA; MAGNESIUM BLOOD LEVEL; MALE; NONHUMAN; POTASSIUM BLOOD LEVEL; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; ANIMAL; BLOOD; BLOOD PRESSURE; DISEASE MODEL; DRUG EFFECTS; KIDNEY; MAGNESIUM DEFICIENCY; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; SYSTOLE; TIME;

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; HYPERTENSION; KIDNEY; MAGNESIUM; MAGNESIUM DEFICIENCY; MALE; RATS; RATS, SPRAGUE-DAWLEY; SYSTOLE; TIME FACTORS;

EID: 84875515295     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2013.28.2.197     Document Type: Article

References (48)

1. Touyz RM. Role of magnesium in the pathogenesis of hypertension. Mol Aspects Med 2003;24:107-136.
2. Laurant P, Dalle M, Berthelot A, Rayssiguier Y. Time-course of the change in blood pressure level in magnesium-deficient Wistar rats. Br J Nutr 1999;82:243-251.
3. Adrian M, Chanut E, Laurant P, Gaume V, Berthelot A. A long-term moderate magnesium-deficient diet aggravates cardiovascular risks associated with aging and increases mortality in rats. J Hypertens 2008;26:44-52.
4. Fox C, Ramsoomair D, Carter C. Magnesium: its proven and potential clinical significance. South Med J 2001;94:1195-1201.
5. Swaminathan R. title typecontributorMagnesium metabolism and its disorders/title. Clin Biochem Rev 2003;24:47-66.
6. Sontia B, Touyz RM. Role of magnesium in hypertension. Arch Biochem Biophys 2007;458:33-39.
7. Berthon N, Laurant P, Hayoz D, Fellmann D, Brunner HR, Berthelot A. Magnesium supplementation and deoxycorticosterone acetate: salt hypertension: effect on arterial mechanical properties and on activity of endothelin-1. Can J Physiol Pharmacol 2002;80:553-561.
8. Blache D, Devaux S, Joubert O, et al. Long-term moderate magnesium-deficient diet shows relationships between blood pressure, inflammation and oxidant stress defense in aging rats. Free Radic Biol Med 2006;41:277-284.
9. Touyz RM. Transient receptor potential melastatin 6 and 7 channels, magnesium transport, and vascular biology: implications in hypertension. Am J Physiol Heart Circ Physiol 2008;294:H1103-H1118.
10. Shechter M, Sharir M, Labrador MJ, Forrester J, Silver B, Bairey Merz CN. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 2000;102:2353-2358.
11. Touyz RM. Magnesium supplementation as an adjuvant to synthetic calcium channel antagonists in the treatment of hypertension. Med Hypotheses 1991;36:140-141.
12. Saito N, Abbu GC, Konishi Y, Nishiyama S, Okada T. Magnesium, calcium and trace elements in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl 1995;22:S212-S214.
13. Makynen H, Kahonen M, Arvola P, Wuorela H, Vapaatalo H, Porsti I. Dietary calcium and magnesium supplements in spontaneously hypertensive rats and isolated arterial reactivity. Br J Pharmacol 1995;115:1455-1462.
14. Evans GH, Weaver CM, Harrington DD, Babbs CF Jr. Dietary magnesium does not affect blood pressure in spontaneously hypertensive rats. Clin Exp Hypertens A 1989;11:619-632.
15. Berthelot A, Esposito J. Effects of dietary magnesium on the development of hypertension in the spontaneously hypertensive rat. J Am Coll Nutr 1983;2:343-353.
16. Touyz RM, Milne FJ. Magnesium supplementation attenuates, but does not prevent, development of hypertension in spontaneously hypertensive rats. Am J Hypertens 1999;12(8 Pt 1):757-765.
17. Laurant P, Touyz RM. Physiological and pathophysiological role of magnesium in the cardiovascular system: implications in hypertension. J Hypertens 2000;18:1177-1191.
18. Touyz RM, Mercure C, Reudelhuber TL. Angiotensin II type I receptor modulates intracellular free Mg2+ in renally derived cells via Na+-dependent Ca2+-independent mechanisms. J Biol Chem 2001;276:13657-13663.
19. Nadler JL, Buchanan T, Natarajan R, Antonipillai I, Bergman R, Rude R. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 1993;21(6 Pt 2):1024-1029.
20. Jin SY, Jeong HJ, Sung SH, et al. Practical standardization in renal biopsy reporting. Korean J Pathol 2010;44:613-622.
21. Resnick LM, Bardicef O, Altura BT, Alderman MH, Altura BM. Serum ionized magnesium: relation to blood pressure and racial factors. Am J Hypertens 1997;10(12 Pt 1):1420-1424.
22. Kesteloot H, Joossens JV. Relationship of dietary sodium, potassium, calcium, and magnesium with blood pressure: Belgian Interuniversity Research on Nutrition and Health. Hypertension 1988;12:594-599.
23. Kisters K, Tepel M, Spieker C, et al. Decreased membrane Mg2+ concentrations in a subgroup of hypertensives: membrane model for the pathogenesis of primary hypertension. Am J Hypertens 1998;11(11 Pt 1):1390-1393.
24. Kawano Y, Matsuoka H, Takishita S, Omae T. Effects of magnesium supplementation in hypertensive patients: assessment by office, home, and ambulatory blood pressures. Hypertension 1998;32:260-265.
25. Laurant P, Kantelip JP, Berthelot A. Dietary magnesium supplementation modif ies blood pressure and cardiovascular function in mineralocorticoid-salt hypertensive rats but not in normotensive rats. J Nutr 1995;125:830-841.
26. Sanjuliani AF, de Abreu Fagundes VG, Francischetti EA. Effects of magnesium on blood pressure and intracellular ion levels of Brazilian hypertensive patients. Int J Cardiol 1996;56:177-183.
27. Widman L, Wester PO, Stegmayr BK, Wirell M. The dose-dependent reduction in blood pressure through administration of magnesium: a double blind placebo controlled cross-over study. Am J Hypertens 1993;6:41-45.
28. Cappuccio FP, Markandu ND, Beynon GW, Shore AC, Sampson B, MacGregor GA. Lack of effect of oral magnesium on high blood pressure: a double blind study. Br Med J (Clin Res Ed) 1985;291:235-238.
29. Ferrara LA, Iannuzzi R, Castaldo A, Iannuzzi A, Dello Russo A, Mancini M. Long-term magnesium supplementation in essential hypertension. Cardiology 1992;81:25-33.
30. Lind L, Lithell H, Pollare T, Ljunghall S. Blood pressure response during long-term treatment with magnesium is dependent on magnesium status: a double-blind, placebo-controlled study in essential hypertension and in subjects with high-normal blood pressure. Am J Hypertens 1991;4:674-679.
31. Barbagallo M, Dominguez LJ, Galioto A, Pineo A, Belvedere M. Oral magnesium supplementation improves vascular function in elderly diabetic patients. Magnes Res 2010;23:131-137.
32. Kisters K. Oral magnesium supplementation improves borderline hypertension. Magnes Res 2011;24:17.
33. RosanoffA. Magnesium supplements may enhance the effect of antihypertensive medications in stage 1 hypertensive subjects. Magnes Res 2010;23:27-40.
34. Hatzistavri LS, Sarafidis PA, Georgianos PI, et al. Oral magnesium supplementation reduces ambulatory blood pressure in patients with mild hypertension. Am J Hypertens 2009;22:1070-1075.
35. Guerrero-Romero F, Rodriguez-Moran M. The effect of lowering blood pressure by magnesium supplementation in diabetic hypertensive adults with low serum magnesium levels: a randomized, double-blind, placebo-controlled clinical trial. J Hum Hypertens 2009;23:245-251.
36. Ameen M, Davies JE, Ng LL. A comparison of free intracellular calcium and magnesium levels in the vascular smooth muscle and striated muscle cells of the spontaneously hypertensive and Wistar Kyoto normotensive rat. Ann N Y Acad Sci 1991;639:550-553.
37. Laurant P, Hayoz D, Brunner HR, Berthelot A. Effect of magnesium deficiency on blood pressure and mechanical properties of rat carotid artery. Hypertension 1999;33:1105-1110.
38. Laurant P, Berthelot A. Inf luence of endothelium on Mg(2+)-induced relaxation in noradrenaline-contracted aorta from DOCA-salt hypertensive rat. Eur J Pharmacol 1994;258:167-172.
39. Touyz RM, Pu Q, He G, et al. Effects of low dietary magnesium intake on development of hypertension in stroke-prone spontaneously hypertensive rats: role of reactive oxygen species. J Hypertens 2002;20:2221-2232.
40. Altura BM, Altura BT, Gebrewold A, Ising H, Gunther T. Noise-induced hypertension and magnesium in rats: relationship to microcirculation and calcium. J Appl Physiol 1992;72:194-202.
41. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
42. Moncada S, Vane JR. The role of prostacyclin in vascular tissue. Fed Proc 1979;38:66-71.
43. Weglicki WB, Phillips TM, Freedman AM, Cassidy MM, Dickens BF. Magnesium-deficiency elevates circulating levels of inflammatory cytokines and endothelin. Mol Cell Biochem 1992;110:169-173.
44. Briel RC, Lippert TH, Zahradnik HP. Action of magnesium sulfate on platelet prostacyclin interaction and prostacyclin of blood vessels. Am J Obstet Gynecol 1985;153:232.
45. Ginn HE, Cade R, McCallum T, Fregley M. Aldosterone secretion in magnesium-deficient rats. Endocrinology 1967;80:969-971.
46. Altura BM, Altura BT. Magnesium and cardiovascular biology: an important link between cardiovascular risk factors and atherogenesis. Cell Mol Biol Res 1995;41:347-359.
47. Yanahira S, Morita M, Aoe S, et al. Effects of lactitol-oligosaccharides on calcium and magnesium absorption in rats. J Nutr Sci Vitaminol (Tokyo) 1997;43:123-132.
48. Iseri LT, French JH. Magnesium: nature's physiologic calcium blocker. Am Heart J 1984;108:188-193.